Organogenesis (NASDAQ:ORGO) Shares Gap Down – Here’s What Happened

Organogenesis Holdings Inc. (NASDAQ:ORGO) shares gapped down prior to trading on Thursday . The stock had previously closed at $4.43, but opened at $4.29. Organogenesis shares last traded at $3.93, with a volume of 540,727 shares.

Organogenesis Stock Performance

The company has a market cap of $495.83 million, a PE ratio of -63.33 and a beta of 1.60. The company has a current ratio of 2.73, a quick ratio of 2.42 and a debt-to-equity ratio of 0.22. The business has a fifty day moving average of $2.97 and a 200-day moving average of $2.81.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. FMR LLC increased its holdings in Organogenesis by 34.2% during the 3rd quarter. FMR LLC now owns 173,595 shares of the company’s stock valued at $496,000 after purchasing an additional 44,199 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Organogenesis by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock valued at $2,713,000 after purchasing an additional 23,675 shares during the period. Intech Investment Management LLC purchased a new position in Organogenesis during the 3rd quarter valued at about $43,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Organogenesis by 5.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 471,240 shares of the company’s stock valued at $1,348,000 after purchasing an additional 24,878 shares during the period. Finally, Metis Global Partners LLC purchased a new position in Organogenesis during the 3rd quarter valued at about $84,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.